Efbemalenograstim alfa, a long-acting granulocyte colony-stimulating factor, a novel dimeric G-CSF Fc fusion protein for reducing the risk of febrile neutropenia following chemotherapy
Journal of Clinical and Experimental Hematology · 2023
DOI: 10.46439/hematol.2.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Hematology, 2023. Verfasst von Simon Xi-Ming Li und 8 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, S. X., Hou, Q., Wang, S., Chen, J., Yao, W., Fu, Y., Liu, L. C., Li, R., & Yan, X. Q. (2023). Efbemalenograstim alfa, a long-acting granulocyte colony-stimulating factor, a novel dimeric G-CSF Fc fusion protein for reducing the risk of febrile neutropenia following chemotherapy. Journal of Clinical and Experimental Hematology. https://doi.org/10.46439/hematol.2.009
Vancouver
Li SX, Hou Q, Wang S, Chen J, Yao W, Fu Y, et al. Efbemalenograstim alfa, a long-acting granulocyte colony-stimulating factor, a novel dimeric G-CSF Fc fusion protein for reducing the risk of febrile neutropenia following chemotherapy. Journal of Clinical and Experimental Hematology. 2023. doi:10.46439/hematol.2.009
BibTeX
@article{Li2023,
author = {Li, Simon Xi-Ming and Hou, Qing-Song and Wang, Shu-Fang and Chen, Jian-Min and Yao, Wei and Fu, Yan-Yan and Liu, Li- Chuan and Li, Ren-Shu and Yan, Xiao Qiang},
title = {Efbemalenograstim alfa, a long-acting granulocyte colony-stimulating factor, a novel dimeric G-CSF Fc fusion protein for reducing the risk of febrile neutropenia following chemotherapy},
journal = {Journal of Clinical and Experimental Hematology},
year = {2023},
doi = {10.46439/hematol.2.009}
}
EUVIMED